Adverse Events Associated With CO-1686

Publication
Article
Special ReportsNSCLC (Issue 3)
Volume 3
Issue 1

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with CO-1686 for patients with non-small cell lung cancer (NSCLC).

Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with the novel EGFR inhibitor CO-1686 for patients with non-small cell lung cancer (NSCLC).

View more on other next-generation therapies for NSCLC > >

Related Videos
Related Content